QXD scientists have demonstrated the capability to develop laterial flow testing with successful prototypes for the COVID SARS 2 virus and Pseudomonas aeruginosa.
QXD scientists developed a lateral flow for SARS-CoV-2 virus detection that is faster and better than other COVID tests. Faster with typically less than 4 minutes due to reading the spike protein versus cracking the molecule to read internal N protein. Better because a positive test via the spike protein means the individual is unequivocally contagious. In contrast, other tests emphasize recognition of the N protein that can be present even after the deletion of the virus from the person. Development required a rigor for use of live virus versus gamma irradiated and heat inactivated virus. Development included a battery of bench testing for Limits of Detection, Cross Reactivity, Endogenous Materials, and Stability/Flex. The technology was tested on over 300 patients, statistically significant with 99.5% accuracy against PCR, sensitivity of 94.1% and specificity of 97%.
QXD also developed a 4-minute test for detection of Pseudomonas aeruginosa. This prototype achieved 85% sensitivity and 100% specificity over 34 patients. Between COVID and Pseudomonas aeruginoa, QXD has developed a well defined process for indentifying the quorum signal compounds. Typical development time to a working prototype is 10 months. QXD is now applying the learning and rigor from COVID and Pseudomonas to the development of a Lateral Flow diagnostic test for Bacterial Vaginosis and Candida albicans.